U.S. Markets close in 4 hrs 15 mins
  • S&P 500

    3,298.35
    -92.33 (-2.72%)
     
  • Dow 30

    26,696.23
    -766.96 (-2.79%)
     
  • Nasdaq

    11,098.39
    -332.96 (-2.91%)
     
  • Russell 2000

    1,550.33
    -40.15 (-2.52%)
     
  • Crude Oil

    37.10
    -2.47 (-6.24%)
     
  • Gold

    1,878.30
    -33.60 (-1.76%)
     
  • Silver

    23.28
    -1.29 (-5.25%)
     
  • EUR/USD

    1.1740
    -0.0050 (-0.4226%)
     
  • 10-Yr Bond

    0.7680
    -0.0100 (-1.29%)
     
  • Vix

    39.56
    +6.21 (+18.62%)
     
  • GBP/USD

    1.3003
    -0.0038 (-0.2913%)
     
  • USD/JPY

    104.2900
    -0.2040 (-0.1952%)
     
  • BTC-USD

    13,201.47
    -508.55 (-3.71%)
     
  • CMC Crypto 200

    261.16
    -11.53 (-4.23%)
     
  • FTSE 100

    5,529.13
    -199.86 (-3.49%)
     
  • Nikkei 225

    23,418.51
    -75.79 (-0.32%)
     

Aquestive Therapeutics (AQST): Strong Industry, Solid Earnings Estimate Revisions

Zacks Equity Research
·2 mins read

One stock that might be an intriguing choice for investors right now is Aquestive Therapeutics, Inc. AQST. This is because this security in the Medical – Drugs space is seeing solid earnings estimate revision activity, and is in great company from a Zacks Industry Rank perspective.

This is important because, often times, a rising tide will lift all boats in an industry, as there can be broad trends taking place in a segment that are boosting securities across the board. This is arguably taking place in the Medical – Drugs space as it currently has a Zacks Industry Rank of 16 out of more than 250 industries, suggesting it is well-positioned from this perspective, especially when compared to other segments out there.

Meanwhile, Aquestive Therapeutics is actually looking pretty good on its own too. The firm has seen solid earnings estimate revision activity over the past month, suggesting analysts are becoming a bit more bullish on the firm’s prospects in both the short and long term.

Aquestive Therapeutics, Inc. Price and Consensus

Aquestive Therapeutics, Inc. Price and Consensus
Aquestive Therapeutics, Inc. Price and Consensus

Aquestive Therapeutics, Inc. price-consensus-chart | Aquestive Therapeutics, Inc. Quote


In fact, over the past month, current quarter estimates have narrowed from a loss of 56 cents per share to a loss of 52 cents per share, while current year estimates have narrowed from a loss of $2.16 per share to a loss of $1.86 per share. This has helped AQST to earn a Zacks Rank #2 (Buy), further underscoring the company’s solid position. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.

So, if you are looking for a decent pick in a strong industry, consider Aquestive Therapeutics. Not only is its industry currently in the top third, but it is seeing solid estimate revisions as of late, suggesting it could be a very interesting choice for investors seeking a name in this great industry segment.

Today's Best Stocks from Zacks

Would you like to see the updated picks from our best market-beating strategies? From 2017 through 2019, while the S&P 500 gained and impressive +53.6%, five of our strategies returned +65.8%, +97.1%, +118.0%, +175.7% and even +186.7%.

This outperformance has not just been a recent phenomenon. From 2000 – 2019, while the S&P averaged +6.0% per year, our top strategies averaged up to +54.7% per year.

See their latest picks free >>


Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
 
Aquestive Therapeutics, Inc. (AQST) : Free Stock Analysis Report
 
To read this article on Zacks.com click here.
 
Zacks Investment Research